Protocol library
SingleNot ApprovedEarly HumanLow confidenceSourced

Melanotan 2

An unapproved cyclic melanocortin analogue with very small early human studies. The published schedules are phase 1 experiments, not a validated tanning protocol.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Human StudySubcutaneousFive alternating-day exposures
Three healthy male volunteers in a phase 1 pilot

Subcutaneous study doses began at 0.01 mg/kg and escalated on alternating study days

Only five active injections were given in a tiny monitored experiment; this cannot establish a routine protocol.

View source
Human StudySubcutaneousTwo monitored exposures
Ten men with organic erectile dysfunction

Two monitored subcutaneous administrations of 0.025 mg/kg in a crossover study

This experiment measured erectile response over six hours and does not establish chronic or cosmetic use.

View source
Community GuideSubcutaneous in guideDaily, then weekly in guide
Third-party educational schedule for a 10 mg research vial

250 mcg daily in week 1, 500 mcg in week 2, 750 mcg in week 3 and 1 mg daily in weeks 4-8; the guide then describes 0.5-1 mg once or twice weekly

This escalation is a community convention, not a validated tanning regimen. It must remain separate from the tiny weight-based phase 1 experiments above.

View source

Evidence summary

An unapproved cyclic melanocortin analogue with very small early human studies. The published schedules are phase 1 experiments, not a validated tanning protocol.

Protocol basis

The only directly matched human protocols are small, short, monitored experiments from the 1990s and 2000. They support an early-human tag but not a general-use schedule.

What remains uncertain

There is no authorised vial, validated long-term regimen or adequate evidence for cosmetic self-administration.

Warnings and contraindications

Melanotan II is not an authorised tanning medicine.
Early studies enrolled only a few participants and reported nausea, fatigue, yawning and prolonged erections.
Unregulated products add unresolved identity, purity, sterility and dose-accuracy risks.